Analyst consensus rating
Whitehawk Therapeutics Analyst Rating: Buy
Direct answer
Whitehawk Therapeutics's consensus rating is Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.50.
Forecast evidence checked September 16, 2026.
Get free Whitehawk Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.09
- Average price target
- $7.50
- High price target
- $10.00
- Low price target
- $4.00
- Low target gap
- -2.2%
- Target upside
- +83.4%
- High target gap
- +144.5%
- Target range width
- 146.7%
- Consensus rating
- Buy
- Analysts
- 6
- Evidence date
- September 16, 2026
- Valid through
- September 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Whitehawk Therapeutics?
Whitehawk Therapeutics has a verified Buy consensus. The same dataset has an average price target of $7.50.
How far are Whitehawk Therapeutics's low and high targets from the recorded price?
The low target implies -2.2%, while the high target implies +144.5%.
How many analysts are included in Whitehawk Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Whitehawk Therapeutics's target upside or downside calculated?
The average target of $7.50 is divided by the recorded price of $4.09, then one is subtracted to produce +83.4%. This does not guarantee a future return.
When was Whitehawk Therapeutics's analyst forecast verified?
The data was verified on 2026-09-16. The dataset is valid through 2026-09-23.